用于即时检测的莱姆病多重血清学诊断测试
研究使用241份严格表征的人血清样本,从12种伯氏疏螺旋体蛋白中筛选3种抗原(VlsE、PepVF、OspC)构建微流控检测(mChip-Ld),并与标准两步法(STT)比较。在特异性设定为95%时,mChip-Ld对早期莱姆病两个血清组的敏感性分别为80%和85%,对莱姆关节炎为100%;STT对相同早期血清组的敏感性分别为48.5%和75%,对莱姆关节炎为100%,特异性为97.5%至100%。mChip-Ld在敏感性上优于STT算法。
要点
- mChip-Ld采用3种抗原(VlsE、PepVF、OspC)可覆盖莱姆病不同阶段。
- 在特异性95%下,mChip-Ld对早期莱姆病敏感性80%和85%,优于STT的48.5%和75%。
- mChip-Ld对莱姆关节炎敏感性100%,与STT相当。
核心结论
- mChip-Ld平台在敏感性上优于标准两步法(STT)算法,为开发单次、快速、多重即时检测提供了可能。
研究设计与样本
- 使用241份严格表征的人血清样本,从12种伯氏疏螺旋体蛋白中筛选最佳抗原构建mChip-Ld,并与第一层酶免疫分析和STT算法比较血清学诊断性能。
主要发现
- 随着莱姆病从早期进展到晚期,更多抗原变为阳性。
- 在特异性设定为95%时,mChip-Ld(3Ag)对两个早期莱姆病血清组的敏感性分别为80%(95%CI 56%至94%)和85%(95%CI 74%至96%),对莱姆关节炎血清的敏感性为100%(95%CI 83%至100%)。
- STT算法对相同两个早期莱姆病血清组的敏感性分别为48.5%和75%,对莱姆关节炎血清的敏感性为100%,特异性为97.5%至100%。
关键数值与推荐
- mChip-Ld包含VlsE、专有合成33-mer肽(PepVF)和OspC三种抗原。
- mChip-Ld在特异性95%下,早期莱姆病敏感性80%和85%,莱姆关节炎100%。
- STT算法早期莱姆病敏感性48.5%和75%,莱姆关节炎100%,特异性97.5%至100%。
临床怎么用
- mChip-Ld可作为单次快速多重检测用于即时检测,并有望设计为识别莱姆病阶段。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Single multiplexed assays could replace the standard 2-tiered (STT) algorithm recommended for the laboratory diagnosis of Lyme disease if they perform with a specificity and a sensitivity superior or equal to those of the STT algorithm. We used human serum rigorously characterized to be sera from patients with acute- and convalescent-phase early Lyme disease, Lyme arthritis, and posttreatment Lyme disease syndrome, as well as the necessary controls (n = 241 samples), to select the best of 12 Borrelia burgdorferi proteins to improve our microfluidic assay (mChip-Ld). We then evaluated its serodiagnostic performance in comparison to that of a first-tier enzyme immunoassay and the STT algorithm. We observed that more antigens became positive as Lyme disease progressed from early to late stages. We selected three antigens (3Ag) to include in the mChip-Ld: VlsE and a proprietary synthetic 33-mer peptide (PepVF) to capture sensitivity in all disease stages and OspC for early Lyme disease. With the specificity set at 95%, the sensitivity of the mChip-Ld with 3Ag ranged from 80% (95% confidence interval [CI], 56% to 94%) and 85% (95% CI, 74% to 96%) for two panels of serum from patients with early Lyme disease and was 100% (95% CI, 83% to 100%) for serum from patients with Lyme arthritis; the STT algorithm detected early Lyme disease in the same two panels of serum from patients with early Lyme disease with a sensitivity of 48.5% and 75% and Lyme arthritis in serum from patients with Lyme arthritis with a sensitivity of 100%, and the specificity was 97.5% to 100%. The mChip-Ld platform outperformed the STT algorithm according to sensitivity. These results open the door for the development of a single, rapid, multiplexed diagnostic test for point-of-care use that can be designed to identify the Lyme disease stage.
引用
- Arumugam S, Nayak S, Williams T, et al. A Multiplexed Serologic Test for Diagnosis of Lyme Disease for Point-of-Care Use. J Clin Microbiol. 2019. PMID: 31597750. doi:10.1128/JCM.01142-19
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。